Literature DB >> 28884440

Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C.

Kazuhide Takata1, Satoshi Shakado2, Keiko Sakamoto3, Hiromi Fukuda2, Ryo Yamauchi2, Sho Fukuda2, Hideo Kunimoto2, Kaoru Umeda2, Takashi Tanaka2, Keiji Yokoyama2, Daisuke Morihara2, Yasuaki Takeyama2, Makoto Irie2, Shotaro Sakisaka2.   

Abstract

Ultrasonography in a 60-year-old man with chronic hepatitis C (CHC) demonstrated multiple hyperechoic nodules. Radiological investigations did not reveal any signs of malignancy. However, magnetic resonance chemical shift imaging showed multiple focal fatty changes in the liver. Urinary levels of uroporphyrin and coproporphyrin were elevated, and we made a diagnosis of porphyria cutanea tarda. Direct-acting antivirals, ledipasvir/sofosbuvir, were initiated for CHC, which led to sustained viral response, resolution of the liver nodules, and normalization of urinary porphyrin. Hepatitis C virus infection can cause porphyria cutanea tarda with multiple hyperechoic liver nodules, which might be cured by direct-acting antivirals.

Entities:  

Keywords:  Direct-acting antivirals; Hepatitis C; Porphyria cutanea tarda; Ultrasonography

Mesh:

Substances:

Year:  2017        PMID: 28884440     DOI: 10.1007/s12328-017-0772-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  22 in total

1.  [Three cases of chronic hepatic porphyria demonstrating the image similar to focal fatty change in the liver].

Authors:  M Komatsu; M Goto; S Ishida; M Niizawa; H Ishida; O Masamune; T Yoshida; S Ito; M Kano; M Murata
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1990-12

2.  Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda.

Authors:  H Takikawa; R Yamazaki; S Shoji; K Miyake; M Yamanaka
Journal:  J Hepatol       Date:  1995-02       Impact factor: 25.083

3.  Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda.

Authors:  A Combalia; J To-Figueras; M Laguno; M Martínez-Rebollar; P Aguilera
Journal:  Br J Dermatol       Date:  2017-09-26       Impact factor: 9.302

4.  Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda.

Authors:  P Aguilera; M Laguno; J To-Figueras
Journal:  Br J Dermatol       Date:  2014-09-24       Impact factor: 9.302

5.  Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients?

Authors:  M M Hatch; Z Nawas; R Kollipara; S K Tyring
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-09-16       Impact factor: 6.166

Review 6.  Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.

Authors:  L E Wiznia; M E Laird; A G Franks
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-03-29       Impact factor: 6.166

7.  Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature.

Authors:  T Y Chuang; R Brashear; C Lewis
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

8.  Multiple nodular foci in the liver associated with chronic hepatic porphyria after previous treatment of breast cancer.

Authors:  W K Lelbach; T R Müller; W Kersjes; J H Hartlapp; M Doss
Journal:  Klin Wochenschr       Date:  1989-06-01

9.  Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association.

Authors:  S Fargion; A Piperno; M D Cappellini; M Sampietro; A L Fracanzani; R Romano; R Caldarelli; R Marcelli; L Vecchi; G Fiorelli
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

10.  Nodular focal fatty infiltration of the liver in acquired porphyria cutanea tarda.

Authors:  F Flueckiger; H Steiner; G Leitinger; S Hoedl; E Deu
Journal:  Gastrointest Radiol       Date:  1991
View more
  2 in total

1.  Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations.

Authors:  Yedidyah Weiss; Brenden Chen; Makiko Yasuda; Irina Nazarenko; Karl E Anderson; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-11-28       Impact factor: 4.797

2.  Porphyria: What Is It and Who Should Be Evaluated?

Authors:  Yonatan Edel; Rivka Mamet
Journal:  Rambam Maimonides Med J       Date:  2018-04-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.